Dan Suesskind Acquires 50,000 Shares of Nano-X Imaging (NASDAQ:NNOX) Stock

Nano-X Imaging Ltd. (NASDAQ:NNOX) Director Dan Suesskind bought 50,000 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The shares were purchased at an average price of $0.93 per share, with a total value of $46,500.00. Following the transaction, the director directly owned 50,000 shares in the company, valued at $46,500. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Nano-X Imaging Stock Up 10.0%

NASDAQ:NNOX opened at $0.96 on Friday. The firm has a market cap of $67.16 million, a PE ratio of -0.61 and a beta of 1.24. Nano-X Imaging Ltd. has a 12 month low of $0.73 and a 12 month high of $4.95. The company’s 50-day moving average price is $1.43 and its two-hundred day moving average price is $2.05.

Nano-X Imaging (NASDAQ:NNOX) last issued its quarterly earnings data on Thursday, June 25th. The company reported ($0.16) earnings per share for the quarter. Nano-X Imaging had a negative return on equity of 70.96% and a negative net margin of 716.44%.The firm had revenue of $4.31 million for the quarter. On average, research analysts expect that Nano-X Imaging Ltd. will post -0.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. D. Boral Capital restated a “buy” rating and set a $5.00 target price on shares of Nano-X Imaging in a report on Monday, April 20th. Alliance Global Partners cut Nano-X Imaging from a “buy” rating to a “neutral” rating and cut their price target for the company from $5.00 to $3.00 in a report on Tuesday, July 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Nano-X Imaging in a report on Wednesday, July 8th. Finally, Zacks Research upgraded shares of Nano-X Imaging from a “strong sell” rating to a “hold” rating in a research report on Monday, June 22nd. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $4.00.

Institutional Investors Weigh In On Nano-X Imaging

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Interchange Capital Partners LLC acquired a new position in shares of Nano-X Imaging during the fourth quarter valued at $28,000. Aristides Capital LLC acquired a new stake in Nano-X Imaging in the fourth quarter worth about $30,000. CIBC Bancorp USA Inc. acquired a new stake in Nano-X Imaging in the third quarter worth about $40,000. Independent Financial Group LLC bought a new stake in Nano-X Imaging during the 1st quarter worth about $26,000. Finally, Kestra Advisory Services LLC bought a new stake in Nano-X Imaging during the 1st quarter worth about $26,000. 21.49% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Nano-X Imaging

Here are the key news stories impacting Nano-X Imaging this week:

• Positive Sentiment: CEO Erez Meltzer bought 36,000 shares at an average price of $0.93, while Director Dan S. Suesskind purchased 50,000 shares at the same price. The combined $79,980 in insider buying may signal that company leadership views NNOX’s depressed valuation as attractive, although the purchases are modest relative to the company’s risks. CEO insider purchase filing Director insider purchase filing
• Neutral Sentiment: Investors are preparing for Nano-X Imaging’s Q2 2026 earnings release. The preview provides an upcoming catalyst, but no new financial results or guidance were included in the report. The market will likely focus on revenue growth, cash burn, operating expenses and progress with the Nanox.ARC imaging platform. Nano-X Imaging Q2 2026 earnings preview
• Negative Sentiment: Bronstein Gewirtz & Grossman and Glancy Prongay Wolke & Rotter announced or promoted a securities class action against NNOX and certain officers. The allegations involve potentially misleading disclosures about cash burn and operating expenses before a reported $17.5 million impairment and manufacturing restructuring. The claims have not been proven, but potential legal costs, reputational damage and uncertainty may pressure the stock. Bronstein class action announcement Glancy class action announcement
• Neutral Sentiment: Several law firms reminded investors of an August 11, 2026 deadline to seek lead-plaintiff status. These notices are primarily legal-firm solicitations rather than new company developments, but their frequency keeps the litigation in focus. Rosen deadline notice

About Nano-X Imaging

Nano-X Imaging Ltd. is a medical technology company developing and commercializing a digital X-ray imaging platform designed to lower the cost and increase the accessibility of diagnostic imaging. Its flagship product, the Nanox.ARC, leverages a proprietary micro-electromechanical system (MEMS) based digital X-ray source and advanced image processing software to provide 2D and 3D imaging capabilities on a compact footprint. The system aims to streamline radiology workflows and facilitate point-of-care diagnostics in hospitals, clinics and outpatient settings.

The Nanox.ARC platform integrates a novel cold cathode X-ray source, which enables multiple emission points without the need for rotating anode tubes.